TREATMENT OF EOSINOPHILIC DISORDERS WITH AVAPRITINIB
The present invention relates to the use of Compound (I) or a pharmaceutically acceptable salt thereof, for the treatment of an eosinophilic disorder, including hypereosinophilic syndrome.
1 . A method of treating an eosinophilic disorder, comprising administering to a subject in need thereof a therapeutically effective amount of Compound (I):
or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the eosinophilic disorder is selected from hypereosinophilic syndrome, eosinophilia, eosinophilic enterogastritis, eosinophilic leukemia, eosinophilic granuloma and Kimura's disease.
3 . The method of claim 1 , wherein the eosinophilic disorder is hypereosinophilic syndrome.
4 . The method of claim 1 , wherein the eosinophilic disorder is eosinophilic leukemia.
5 . The method of claim 4 , wherein the eosinophilic leukemia is chronic eosinophilic leukemia.
6 . The method of claim 1 , wherein the eosinophilic disorder is refractory to treatment with imatinib, sunitinib, and/or regorafenib.
7 . The method of claim 1 , wherein the subject has a mutation in Exon 17 in KIT.
8 . The method of claim 1 , wherein the subject has a D816 mutation in KIT in Exon 17.
9 . The method of claim 8 , wherein the D816 mutation is D816V.
10 . The method of claim 8 , wherein the D816 mutation is D816Y.
11 . The method of claim 1 , wherein the therapeutically effective amount is 30-400 mg.
12 . The method of claim 1 , wherein the therapeutically effective amount is 100-300 mg per day.
13 . The method of claim 1 , wherein the therapeutically effective amount is 100 mg per day.
14 . The method of claim 1 , wherein the therapeutically effective amount is 200 mg per day.
15 . The method of claim 1 , wherein the therapeutically effective amount is 300 mg per day.
16 . A method of reducing the number of eosinophils in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Compound (I):
or a pharmaceutically acceptable salt thereof.
17 . The method of claim 16 , wherein there is a post-administration reduction in absolute eosinophil count of at least 20%.
18 . The method of claim 16 , wherein there is a post-administration reduction in absolute eosinophil count of at least 30%.
19 . The method of claim 16 , wherein there is a post-administration reduction in absolute eosinophil count of at least 40%.
20 . The method of claim 16 , wherein there is a post-administration reduction in absolute eosinophil count of at least 50%.
21 - 23 . (canceled)